{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:40:14Z","timestamp":1787330414290,"version":"build-2736575974"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09824-9","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T03:57:17Z","timestamp":1787284637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming resistance to immune checkpoint inhibitors in cancer: translational mechanisms, dynamic biomarkers, clinically actionable combination strategies, and comparative checkpoint biology"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3218-5212","authenticated-orcid":false,"given":"Rumeysa Berra","family":"Karata\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9920-5931","authenticated-orcid":false,"given":"Yaren","family":"Alras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7200-9658","authenticated-orcid":false,"given":"Sarenur","family":"Teki\u0307ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3478-9754","authenticated-orcid":false,"given":"Kaan","family":"Z\u0131k\u015fahna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7036-1115","authenticated-orcid":false,"given":"Selim","family":"Merdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-5638","authenticated-orcid":false,"given":"Murat","family":"Ihlamur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"2","key":"9824_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.29048\/makufebed.569375","volume":"10","author":"K Kahveci","year":"2019","unstructured":"Kahveci K, T\u00fcrko\u011flu M. \u0130mm\u00fcn Kontrol Noktas\u0131 \u0130nhibit\u00f6rleri Ctla-4 ve Pd-1\/Pd-l1\u2019in \u0130mm\u00fcnoterapideki Yeri. Mehmet Akif Ersoy \u00dcniversitesi Fen Bilimleri Enstit\u00fcs\u00fc Dergisi. 2019;10(2):210\u20138. https:\/\/doi.org\/10.29048\/makufebed.569375.","journal-title":"Mehmet Akif Ersoy \u00dcniversitesi Fen Bilimleri Enstit\u00fcs\u00fc Dergisi"},{"issue":"1","key":"9824_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-immunol-083122-040624","volume":"43","author":"KA Warrick","year":"2025","unstructured":"Warrick KA, Vallez CN, Meibers HE, Pasare C. Bidirectional Communication Between the Innate and Adaptive Immune Systems. Annu Rev Immunol. 2025;43(1):489\u2013514. https:\/\/doi.org\/10.1146\/annurev-immunol-083122-040624.","journal-title":"Annu Rev Immunol"},{"key":"9824_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4274\/atfm.galenos.2019.24382","volume":"72","author":"\u00d6 Ba\u015f Aksu","year":"2020","unstructured":"Ba\u015f Aksu \u00d6, \u015eeng\u00fcl \u015e. Immune Checkpoints and Inhibitors. J Ankara Univ Fac Med. 2020;72:262\u20137. https:\/\/doi.org\/10.4274\/atfm.galenos.2019.24382.","journal-title":"J Ankara Univ Fac Med"},{"issue":"Pt 2","key":"9824_CR4","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365. https:\/\/doi.org\/10.1016\/j.intimp.2024.113365.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"9824_CR5","doi-asserted-by":"publisher","first-page":"e70196","DOI":"10.1002\/iid3.70196","volume":"13","author":"E Rezazadeh-Gavgani","year":"2025","unstructured":"Rezazadeh-Gavgani E, Majidazar R, Lotfinejad P, Kazemi T, Shamekh A. Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. Immun Inflamm Dis. 2025;13(4):e70196. https:\/\/doi.org\/10.1002\/iid3.70196.","journal-title":"Immun Inflamm Dis"},{"issue":"2","key":"9824_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbcan.2017.10.006","volume":"1868","author":"F Marcucci","year":"2017","unstructured":"Marcucci F, Rumio C, Corti A. Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. Biochim Biophys Acta Rev Cancer. 2017;1868(2):571\u201383. https:\/\/doi.org\/10.1016\/j.bbcan.2017.10.006.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"9824_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","volume":"1248","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol. 2020;1248:201\u201326. https:\/\/doi.org\/10.1007\/978-981-15-3266-5_9.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"9824_CR8","doi-asserted-by":"publisher","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","volume":"4","author":"E Jenkins","year":"2023","unstructured":"Jenkins E, Whitehead T, Fellermeyer M, Davis SJ, Sharma S. The current state and future of T-cell exhaustion research. Oxf Open Immunol. 2023;4(1):iqad006. https:\/\/doi.org\/10.1093\/oxfimm\/iqad006.","journal-title":"Oxf Open Immunol"},{"issue":"6024","key":"9824_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"issue":"11","key":"9824_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138. https:\/\/doi.org\/10.1038\/ni1102-991.","journal-title":"Nat Immunol"},{"issue":"18","key":"9824_CR11","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1158\/1078-0432.Ccr-21-1804","volume":"28","author":"MM Gubin","year":"2022","unstructured":"Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clin Cancer Res. 2022;28(18):3917\u201328. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1804.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9824_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.011.","journal-title":"Immunity"},{"key":"9824_CR13","doi-asserted-by":"publisher","unstructured":"Trontzas IP, Syrigos KN. Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies. Cancers (Basel). 2025;17(16). https:\/\/doi.org\/10.3390\/cancers17162639.","DOI":"10.3390\/cancers17162639"},{"issue":"9","key":"9824_CR14","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.Ccr-23-1014","volume":"30","author":"SH Lim","year":"2024","unstructured":"Lim SH, Beers SA, Al-Shamkhani A, Cragg MS. Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clin Cancer Res. 2024;30(9):1712\u201323. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1014.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9824_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10(1):227. https:\/\/doi.org\/10.1038\/s41392-025-02280-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 2","key":"9824_CR16","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(Suppl 2):S87\u201397. https:\/\/doi.org\/10.3747\/co.27.5223.","journal-title":"Curr Oncol"},{"key":"9824_CR17","doi-asserted-by":"publisher","first-page":"217616","DOI":"10.1016\/j.canlet.2025.217616","volume":"617","author":"J Wang","year":"2025","unstructured":"Wang J, Chen Q, Shan Q, Liang T, Forde P, Zheng L. Clinical development of immuno-oncology therapeutics. Cancer Lett. 2025;617:217616. https:\/\/doi.org\/10.1016\/j.canlet.2025.217616.","journal-title":"Cancer Lett"},{"issue":"8","key":"9824_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"9824_CR19","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1002\/ctd2.70001","volume":"4","author":"L Li","year":"2024","unstructured":"Li L, Sun Y. Challenges and advances of immune checkpoint therapy. Clin Translational Discovery. 2024;4(6):e70001. https:\/\/doi.org\/10.1002\/ctd2.70001.","journal-title":"Clin Translational Discovery"},{"issue":"3","key":"9824_CR20","doi-asserted-by":"publisher","first-page":"e431608","DOI":"10.1200\/edbk_431608","volume":"44","author":"J Haanen","year":"2024","unstructured":"Haanen J, Los C, Phan GQ, Betof Warner A. Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies. Am Soc Clin Oncol Educ Book. 2024;44(3):e431608. https:\/\/doi.org\/10.1200\/edbk_431608.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9824_CR21","doi-asserted-by":"publisher","first-page":"1680838","DOI":"10.3389\/fimmu.2025.1680838","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Sk\u00e5lhegg BS. Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. Front Immunol. 2025;16:1680838. https:\/\/doi.org\/10.3389\/fimmu.2025.1680838.","journal-title":"Front Immunol"},{"key":"9824_CR22","doi-asserted-by":"publisher","first-page":"1493877","DOI":"10.3389\/fimmu.2024.1493877","volume":"15","author":"E Poddubskaya","year":"2024","unstructured":"Poddubskaya E, Suntsova M, Lyadova M, Luppov D, Guryanova A, Lyadov V, et al. Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients. Front Immunol. 2024;15:1493877. https:\/\/doi.org\/10.3389\/fimmu.2024.1493877.","journal-title":"Front Immunol"},{"issue":"16","key":"9824_CR23","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.Ccr-24-0517","volume":"30","author":"SJ Casak","year":"2024","unstructured":"Casak SJ, Kumar V, Song C, Yuan M, Amatya AK, Cheng J, et al. FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clin Cancer Res. 2024;30(16):3371\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0517.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9824_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","volume":"83","author":"DY Oh","year":"2025","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Kim JW, et al. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. J Hepatol. 2025;83(5):1092\u2013101. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.003.","journal-title":"J Hepatol"},{"issue":"2","key":"9824_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1159\/000490025","volume":"47","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Yang W, Huang Y, Cui R, Li X, Li B. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cell Physiol Biochem. 2018;47(2):721\u201334. https:\/\/doi.org\/10.1159\/000490025.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"9824_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/coc.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106. https:\/\/doi.org\/10.1097\/coc.0000000000000239.","journal-title":"Am J Clin Oncol"},{"key":"9824_CR27","doi-asserted-by":"publisher","first-page":"107458","DOI":"10.1016\/j.phrs.2024.107458","volume":"209","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang L, Guo H, Kong S, Li W, He Q, et al. The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells. Pharmacol Res. 2024;209:107458. https:\/\/doi.org\/10.1016\/j.phrs.2024.107458.","journal-title":"Pharmacol Res"},{"key":"9824_CR28","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.intimp.2021.107933","volume":"99","author":"L Zhao","year":"2021","unstructured":"Zhao L, Cheng S, Fan L, Zhang B, Xu S. TIM-3: An update on immunotherapy. Int Immunopharmacol. 2021;99:107933. https:\/\/doi.org\/10.1016\/j.intimp.2021.107933.","journal-title":"Int Immunopharmacol"},{"key":"9824_CR29","doi-asserted-by":"publisher","first-page":"1568664","DOI":"10.3389\/fphar.2025.1568664","volume":"16","author":"K Ghasemi","year":"2025","unstructured":"Ghasemi K. Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Front Pharmacol. 2025;16:1568664. https:\/\/doi.org\/10.3389\/fphar.2025.1568664.","journal-title":"Front Pharmacol"},{"issue":"1","key":"9824_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/imr.13388","volume":"328","author":"HAD King","year":"2024","unstructured":"King HAD, Lewin SR. Immune checkpoint inhibitors in infectious disease. Immunol Rev. 2024;328(1):350\u201371. https:\/\/doi.org\/10.1111\/imr.13388.","journal-title":"Immunol Rev"},{"key":"9824_CR31","doi-asserted-by":"publisher","first-page":"1646292","DOI":"10.3389\/fimmu.2025.1646292","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Song S. Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach. Front Immunol. 2025;16:1646292. https:\/\/doi.org\/10.3389\/fimmu.2025.1646292.","journal-title":"Front Immunol"},{"issue":"17","key":"9824_CR32","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune Checkpoint Inhibitors: Basics and Challenges. Curr Med Chem. 2019;26(17):3009\u201325. https:\/\/doi.org\/10.2174\/0929867324666170804143706.","journal-title":"Curr Med Chem"},{"key":"9824_CR33","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975. https:\/\/doi.org\/10.3389\/fimmu.2023.1167975.","journal-title":"Front Immunol"},{"issue":"1","key":"9824_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s40001-023-01365-3","volume":"28","author":"P Ding","year":"2023","unstructured":"Ding P, Liu P, Meng L, Zhao Q. Mechanisms and biomarkers of immune-related adverse events in gastric cancer. Eur J Med Res. 2023;28(1):492. https:\/\/doi.org\/10.1186\/s40001-023-01365-3.","journal-title":"Eur J Med Res"},{"issue":"3","key":"9824_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367. https:\/\/doi.org\/10.1038\/nri.2017.108.","journal-title":"Nat Rev Immunol"},{"key":"9824_CR36","doi-asserted-by":"publisher","first-page":"1347181","DOI":"10.3389\/fimmu.2024.1347181","volume":"15","author":"L Xuekai","year":"2024","unstructured":"Xuekai L, Yan S, Jian C, Yifei S, Xinyue W, Wenyuan Z, et al. Advances in reprogramming of energy metabolism in tumor T cells. Front Immunol. 2024;15:1347181. https:\/\/doi.org\/10.3389\/fimmu.2024.1347181.","journal-title":"Front Immunol"},{"issue":"10","key":"9824_CR37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s44161-025-00713-2","volume":"4","author":"M Mulholland","year":"2025","unstructured":"Mulholland M, Chalou A, Andersson SHA, Depuydt MAC, Yu Y, Lin S, et al. Progenitor exhausted PD-1\u2009+\u2009T cells are cellular targets of immune checkpoint inhibition in atherosclerosis. Nat Cardiovasc Res. 2025;4(10):1311\u201328. https:\/\/doi.org\/10.1038\/s44161-025-00713-2.","journal-title":"Nat Cardiovasc Res"},{"key":"9824_CR38","doi-asserted-by":"publisher","unstructured":"Buckle I, Guillerey C. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. Cancers (Basel). 2021;13(17). https:\/\/doi.org\/10.3390\/cancers13174263.","DOI":"10.3390\/cancers13174263"},{"key":"9824_CR39","doi-asserted-by":"publisher","unstructured":"Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1\/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel). 2021;14(1). https:\/\/doi.org\/10.3390\/cancers14010109.","DOI":"10.3390\/cancers14010109"},{"key":"9824_CR40","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961. https:\/\/doi.org\/10.3389\/fimmu.2022.1070961.","journal-title":"Front Immunol"},{"key":"9824_CR41","doi-asserted-by":"publisher","unstructured":"Monette A, Warren S, Barrett JC, Garnett-Benson C, Schalper KA, Taube JM, et al. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee. J Immunother Cancer. 2024;12(7). https:\/\/doi.org\/10.1136\/jitc-2024-009427.","DOI":"10.1136\/jitc-2024-009427"},{"key":"9824_CR42","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: From mechanism to autoimmune therapy. Int Immunopharmacol. 2020;80:106221. https:\/\/doi.org\/10.1016\/j.intimp.2020.106221.","journal-title":"Int Immunopharmacol"},{"key":"9824_CR43","doi-asserted-by":"publisher","first-page":"1688699","DOI":"10.3389\/fimmu.2025.1688699","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, He J, Ding G, Tang Y, Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699. https:\/\/doi.org\/10.3389\/fimmu.2025.1688699.","journal-title":"Front Immunol"},{"issue":"3","key":"9824_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/immuno4030013","volume":"4","author":"A Younis","year":"2024","unstructured":"Younis A, Gribben J. Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions. Immuno. 2024;4(3):186\u2013210.","journal-title":"Immuno"},{"issue":"1","key":"9824_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033.","journal-title":"Blood"},{"key":"9824_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","volume":"1248","author":"S Van Coillie","year":"2020","unstructured":"Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4. Adv Exp Med Biol. 2020;1248:7\u201332. https:\/\/doi.org\/10.1007\/978-981-15-3266-5_2.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"9824_CR47","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, Shimizu K, Maeda TK, Ikubo J, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022;55(5):912\u2013e248. https:\/\/doi.org\/10.1016\/j.immuni.2022.03.013.","journal-title":"Immunity"},{"issue":"6","key":"9824_CR48","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11912-023-01406-4","volume":"25","author":"LJ Albrecht","year":"2023","unstructured":"Albrecht LJ, Livingstone E, Zimmer L, Schadendorf D. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. Curr Oncol Rep. 2023;25(6):647\u201357. https:\/\/doi.org\/10.1007\/s11912-023-01406-4.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"9824_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","volume":"9","author":"N Yin","year":"2024","unstructured":"Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct Target Therapy. 2024;9(1):126. https:\/\/doi.org\/10.1038\/s41392-024-01826-z.","journal-title":"Signal Transduct Target Therapy"},{"issue":"12","key":"9824_CR50","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","volume":"24","author":"MT Lotze","year":"2024","unstructured":"Lotze MT, Olejniczak SH, Skokos D. CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol. 2024;24(12):878\u201395. https:\/\/doi.org\/10.1038\/s41577-024-01061-1.","journal-title":"Nat Rev Immunol"},{"key":"9824_CR51","doi-asserted-by":"publisher","unstructured":"Kaur M, R\u00fcger K, Chen EC, Rangaswamy US, Davison LM, Moreno Arteaga S, et al. Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers. J Immunother Cancer. 2025;13(4). https:\/\/doi.org\/10.1136\/jitc-2024-011323.","DOI":"10.1136\/jitc-2024-011323"},{"issue":"1","key":"9824_CR52","doi-asserted-by":"publisher","first-page":"e71467","DOI":"10.1002\/cam4.71467","volume":"15","author":"M Nikanjam","year":"2026","unstructured":"Nikanjam M, Kato S, Nishizaki D, Miyashita H, Pabla S, Nesline MK, et al. Inducible T-Cell Co-Stimulator (ICOS) and ICOS Ligand: Dealing With a Two-Faced Cancer Immunoregulatory System. Cancer Med. 2026;15(1):e71467. https:\/\/doi.org\/10.1002\/cam4.71467.","journal-title":"Cancer Med"},{"issue":"3","key":"9824_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00262-023-03623-z","volume":"73","author":"JF Hilton","year":"2024","unstructured":"Hilton JF, Ott PA, Hansen AR, Li Z, Mathew M, Messina CH, et al. INDUCE-2: A Phase I\/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2024;73(3):44. https:\/\/doi.org\/10.1007\/s00262-023-03623-z.","journal-title":"Cancer Immunol Immunother"},{"key":"9824_CR54","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.17179\/excli2021-3522","volume":"20","author":"R Pourakbari","year":"2021","unstructured":"Pourakbari R, Hajizadeh F, Parhizkar F, Aghebati-Maleki A, Mansouri S, Aghebati-Maleki L. Co-stimulatory agonists: An insight into the immunotherapy of cancer. Excli j. 2021;20:1055\u201385. https:\/\/doi.org\/10.17179\/excli2021-3522.","journal-title":"Excli j"},{"key":"9824_CR55","doi-asserted-by":"publisher","unstructured":"Honikel MM, Olejniczak SH. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022;12(9). https:\/\/doi.org\/10.3390\/biom12091303.","DOI":"10.3390\/biom12091303"},{"issue":"1","key":"9824_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00280-025-04809-1","volume":"95","author":"J Desai","year":"2025","unstructured":"Desai J, Deva S, Gao B, Yang K, O\u2019Byrne KJ, Sun M, et al. A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results. Cancer Chemother Pharmacol. 2025;95(1):99. https:\/\/doi.org\/10.1007\/s00280-025-04809-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9824_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","volume":"56","author":"R Singh","year":"2024","unstructured":"Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024;56(1):32\u20139. https:\/\/doi.org\/10.1038\/s12276-023-01136-4.","journal-title":"Exp Mol Med"},{"key":"9824_CR58","doi-asserted-by":"publisher","unstructured":"Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, et al. Phase I\/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024;12(10). https:\/\/doi.org\/10.1136\/jitc-2024-009975.","DOI":"10.1136\/jitc-2024-009975"},{"issue":"11","key":"9824_CR59","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1078-0432.Ccr-24-1660","volume":"31","author":"JC McVey","year":"2025","unstructured":"McVey JC, Beatty GL. Facts and Hopes of CD40 Agonists in Cancer Immunotherapy. Clin Cancer Res. 2025;31(11):2079\u201387. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1660.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 3","key":"9824_CR60","doi-asserted-by":"publisher","first-page":"e000738","DOI":"10.1136\/esmoopen-2020-000738","volume":"4","author":"G Buzzatti","year":"2020","unstructured":"Buzzatti G, Dellepiane C, Del Mastro L. New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open. 2020;4(Suppl 3):e000738. https:\/\/doi.org\/10.1136\/esmoopen-2020-000738.","journal-title":"ESMO Open"},{"issue":"2","key":"9824_CR61","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","volume":"25","author":"AE Moran","year":"2013","unstructured":"Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013;25(2):230\u20137. https:\/\/doi.org\/10.1016\/j.coi.2013.01.004.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"9824_CR62","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jcph.591","volume":"56","author":"L Lee","year":"2016","unstructured":"Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56(2):157\u201369. https:\/\/doi.org\/10.1002\/jcph.591.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9824_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41416-024-02698-4","volume":"131","author":"H Jeong","year":"2024","unstructured":"Jeong H, Koh J, Kim S, Song SG, Lee SH, Jeon Y, et al. Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. Br J Cancer. 2024;131(1):23\u201336. https:\/\/doi.org\/10.1038\/s41416-024-02698-4.","journal-title":"Br J Cancer"},{"issue":"1","key":"9824_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13046-025-03514-4","volume":"44","author":"OJ Hussein","year":"2025","unstructured":"Hussein OJ, Rayan M, Matarid TR, Elkhalifa D, Abunada HH, Therachiyil L, et al. The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy. J Exp Clin Cancer Res. 2025;44(1):305. https:\/\/doi.org\/10.1186\/s13046-025-03514-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"9824_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024;42(1):179\u2013206. https:\/\/doi.org\/10.1146\/annurev-immunol-090222-110914.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"9824_CR66","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"key":"9824_CR67","doi-asserted-by":"publisher","first-page":"1084887","DOI":"10.3389\/fimmu.2023.1084887","volume":"14","author":"A Tiwari","year":"2023","unstructured":"Tiwari A, Oravecz T, Dillon LA, Italiano A, Audoly L, Fridman WH, et al. Towards a consensus definition of immune exclusion in cancer. Front Immunol. 2023;14:1084887. https:\/\/doi.org\/10.3389\/fimmu.2023.1084887.","journal-title":"Front Immunol"},{"issue":"5","key":"9824_CR68","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","volume":"42","author":"D Dyikanov","year":"2024","unstructured":"Dyikanov D, Zaitsev A, Vasileva T, Wang I, Sokolov AA, Bolshakov ES, et al. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer Cell. 2024;42(5):759\u2013e7912. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.008.","journal-title":"Cancer Cell"},{"issue":"1","key":"9824_CR69","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80. https:\/\/doi.org\/10.1186\/s40164-024-00543-1.","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"9824_CR70","doi-asserted-by":"publisher","first-page":"e70321","DOI":"10.1002\/mco2.70321","volume":"6","author":"Y Peng","year":"2025","unstructured":"Peng Y, Zhan L, Shi J, Wang J, Li Y, Sun X, et al. Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy. MedComm (2020). 2025;6(10):e70321. https:\/\/doi.org\/10.1002\/mco2.70321.","journal-title":"MedComm (2020)"},{"issue":"10","key":"9824_CR71","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/1541-7786.Mcr-25-0251","volume":"23","author":"Z Wang","year":"2025","unstructured":"Wang Z, Du X, Xing X, Xie W, Xin H, Liu W. Myeloid-Derived Suppressor Cells: Orchestrators of Tumor Immune Evasion and Therapeutic Vulnerabilities. Mol Cancer Res. 2025;23(10):829\u201338. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-25-0251.","journal-title":"Mol Cancer Res"},{"key":"9824_CR72","doi-asserted-by":"publisher","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022;13:868695. https:\/\/doi.org\/10.3389\/fphar.2022.868695.","journal-title":"Front Pharmacol"},{"issue":"3","key":"9824_CR73","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.009.","journal-title":"Cancer Cell"},{"key":"9824_CR74","doi-asserted-by":"publisher","first-page":"1172931","DOI":"10.3389\/fimmu.2023.1172931","volume":"14","author":"S Ganjoo","year":"2023","unstructured":"Ganjoo S, Gupta P, Corbali HI, Nanez S, Riad TS, Duong LK, et al. The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol. 2023;14:1172931. https:\/\/doi.org\/10.3389\/fimmu.2023.1172931.","journal-title":"Front Immunol"},{"issue":"10","key":"9824_CR75","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149(10):8131\u201341. https:\/\/doi.org\/10.1007\/s00432-023-04737-8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"9824_CR76","doi-asserted-by":"publisher","first-page":"116463","DOI":"10.1016\/j.celrep.2025.116463","volume":"44","author":"S Li","year":"2025","unstructured":"Li S, Zhang Y, Tong H, Sun H, Liao H, Li Q, et al. Metabolic regulation of immunity in the tumor microenvironment. Cell Rep. 2025;44(11):116463. https:\/\/doi.org\/10.1016\/j.celrep.2025.116463.","journal-title":"Cell Rep"},{"issue":"20","key":"9824_CR77","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1042\/bcj20210233","volume":"479","author":"Q Wei","year":"2022","unstructured":"Wei Q, Task\u00e9n K. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochem J. 2022;479(20):2219\u201360. https:\/\/doi.org\/10.1042\/bcj20210233.","journal-title":"Biochem J"},{"issue":"2","key":"9824_CR78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back. BioDrugs. 2025;39(2):215\u201335. https:\/\/doi.org\/10.1007\/s40259-024-00700-2.","journal-title":"BioDrugs"},{"issue":"1","key":"9824_CR79","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/clinpract13010003","volume":"13","author":"AM Basudan","year":"2022","unstructured":"Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract. 2022;13(1):22\u201340. https:\/\/doi.org\/10.3390\/clinpract13010003.","journal-title":"Clin Pract"},{"issue":"1","key":"9824_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41698-025-01123-0","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guo Y, Tan AC, Zhao L, Shi X, Chen Y, et al. A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors. npj Precision Oncol. 2025;9(1):346. https:\/\/doi.org\/10.1038\/s41698-025-01123-0.","journal-title":"npj Precision Oncol"},{"key":"9824_CR81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fonc.2018.00080","volume":"8","author":"R Anderson","year":"2018","unstructured":"Anderson R, Rapoport BL. Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. Front Oncol. 2018;8:80. https:\/\/doi.org\/10.3389\/fonc.2018.00080.","journal-title":"Front Oncol"},{"key":"9824_CR82","doi-asserted-by":"publisher","first-page":"216182","DOI":"10.1016\/j.canlet.2023.216182","volume":"562","author":"C Zhang","year":"2023","unstructured":"Zhang C, Zhang C, Wang H. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. Cancer Lett. 2023;562:216182. https:\/\/doi.org\/10.1016\/j.canlet.2023.216182.","journal-title":"Cancer Lett"},{"issue":"7","key":"9824_CR83","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/imcb.12646","volume":"101","author":"AM Chenoweth","year":"2023","unstructured":"Chenoweth AM, Esparon S, Wines BD, Schuurman J, Labrijn AF, Hogarth PM. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific Fc\u03b3RIIb binding and retention of super-agonist activity. Immunol Cell Biol. 2023;101(7):657\u201362. https:\/\/doi.org\/10.1111\/imcb.12646.","journal-title":"Immunol Cell Biol"},{"key":"9824_CR84","doi-asserted-by":"publisher","first-page":"823842","DOI":"10.3389\/fimmu.2022.823842","volume":"13","author":"BL Rapoport","year":"2022","unstructured":"Rapoport BL, Steel HC, Hlatshwayo N, Theron AJ, Meyer PWA, Nayler S, et al. Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules. Front Immunol. 2022;13:823842. https:\/\/doi.org\/10.3389\/fimmu.2022.823842.","journal-title":"Front Immunol"},{"key":"9824_CR85","doi-asserted-by":"publisher","first-page":"1097309","DOI":"10.3389\/fonc.2023.1097309","volume":"13","author":"BL Rapoport","year":"2023","unstructured":"Rapoport BL, Steel HC, Benn CA, Nayler S, Smit T, Heyman L, et al. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3. Front Oncol. 2023;13:1097309. https:\/\/doi.org\/10.3389\/fonc.2023.1097309.","journal-title":"Front Oncol"},{"key":"9824_CR86","doi-asserted-by":"publisher","first-page":"1298571","DOI":"10.3389\/fimmu.2023.1298571","volume":"14","author":"LV Mej\u00eda-Guarnizo","year":"2023","unstructured":"Mej\u00eda-Guarnizo LV, Monroy-Camacho PS, Turizo-Smith AD, Rodr\u00edguez-Garc\u00eda JA. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. Front Immunol. 2023;14:1298571. https:\/\/doi.org\/10.3389\/fimmu.2023.1298571.","journal-title":"Front Immunol"},{"issue":"12","key":"9824_CR87","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","volume":"7","author":"L Maggs","year":"2021","unstructured":"Maggs L, Sadagopan A, Moghaddam AS, Ferrone S. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends Cancer. 2021;7(12):1089\u2013101. https:\/\/doi.org\/10.1016\/j.trecan.2021.07.006.","journal-title":"Trends Cancer"},{"issue":"1","key":"9824_CR88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41698-024-00665-z","volume":"8","author":"A Lozac\u2019hmeur","year":"2024","unstructured":"Lozac\u2019hmeur A, Danek T, Yang Q, Rosasco MG, Welch JS, Go WY, et al. Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities. npj Precision Oncol. 2024;8(1):174. https:\/\/doi.org\/10.1038\/s41698-024-00665-z.","journal-title":"npj Precision Oncol"},{"issue":"31","key":"9824_CR89","doi-asserted-by":"publisher","first-page":"e2300895120","DOI":"10.1073\/pnas.2300895120","volume":"120","author":"BM Lax","year":"2023","unstructured":"Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proc Natl Acad Sci U S A. 2023;120(31):e2300895120. https:\/\/doi.org\/10.1073\/pnas.2300895120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9824_CR90","doi-asserted-by":"publisher","first-page":"113501","DOI":"10.1016\/j.ejca.2023.113501","volume":"198","author":"AM Di Giacomo","year":"2024","unstructured":"Di Giacomo AM, Lahn M, Eggermont AM, Fox B, Ibrahim R, Sharma P, et al. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? Eur J Cancer. 2024;198:113501. https:\/\/doi.org\/10.1016\/j.ejca.2023.113501.","journal-title":"Eur J Cancer"},{"issue":"3","key":"9824_CR91","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727\u201342.","journal-title":"Am J Cancer Res"},{"issue":"12","key":"9824_CR92","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, Cho M, Kim E, Seo Y, Cha JH. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024;32(12):4235\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.026.","journal-title":"Mol Ther"},{"key":"9824_CR93","doi-asserted-by":"publisher","first-page":"104980","DOI":"10.1016\/j.critrevonc.2025.104980","volume":"216","author":"EO Oisakede","year":"2025","unstructured":"Oisakede EO, Akinro O, Bello OJ, Analikwu CC, Egbon E, Olawade DB. Predictive models for immune checkpoint inhibitor response in cancer: A review of current approaches and future directions. Crit Rev Oncol Hematol. 2025;216:104980. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104980.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"9824_CR94","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w.","journal-title":"Mol Cancer"},{"key":"9824_CR95","doi-asserted-by":"publisher","unstructured":"Zhang J, Hu C, Xie X, Qi L, Li C, Li S. Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy. Vaccines (Basel). 2023;11(3). https:\/\/doi.org\/10.3390\/vaccines11030614.","DOI":"10.3390\/vaccines11030614"},{"issue":"1","key":"9824_CR96","doi-asserted-by":"publisher","first-page":"e1005349","DOI":"10.1371\/journal.ppat.1005349","volume":"12","author":"GM Chew","year":"2016","unstructured":"Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog. 2016;12(1):e1005349. https:\/\/doi.org\/10.1371\/journal.ppat.1005349.","journal-title":"PLoS Pathog"},{"issue":"6","key":"9824_CR97","doi-asserted-by":"publisher","first-page":"e0027324","DOI":"10.1128\/jvi.00273-24","volume":"98","author":"GM Webb","year":"2024","unstructured":"Webb GM, Pessoa CT, McCullen AJ, Hwang JM, Humkey MC, Thormin-Odum R, et al. Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection. J Virol. 2024;98(6):e0027324. https:\/\/doi.org\/10.1128\/jvi.00273-24.","journal-title":"J Virol"},{"key":"9824_CR98","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","volume":"10","author":"Y Chen","year":"2019","unstructured":"Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol. 2019;10:2048. https:\/\/doi.org\/10.3389\/fimmu.2019.02048.","journal-title":"Front Immunol"},{"issue":"1","key":"9824_CR99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","volume":"82","author":"HC Mon","year":"2025","unstructured":"Mon HC, Lee PC, Hung YP, Hung YW, Wu CJ, Lee CJ, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2025;82(1):51\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.018.","journal-title":"J Hepatol"},{"key":"9824_CR100","doi-asserted-by":"publisher","first-page":"1379622","DOI":"10.3389\/fimmu.2024.1379622","volume":"15","author":"Z Akbulut","year":"2024","unstructured":"Akbulut Z, Aru B, Ayd\u0131n F, Yan\u0131kkaya Demirel G. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Front Immunol. 2024;15:1379622. https:\/\/doi.org\/10.3389\/fimmu.2024.1379622.","journal-title":"Front Immunol"},{"issue":"2","key":"9824_CR101","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.26512","volume":"93","author":"X Boumaza","year":"2023","unstructured":"Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, et al. Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors. Ann Neurol. 2023;93(2):257\u201370. https:\/\/doi.org\/10.1002\/ana.26512.","journal-title":"Ann Neurol"},{"key":"9824_CR102","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.5318","author":"N M\u00f6hn","year":"2026","unstructured":"M\u00f6hn N, Grote-Levi L, Bonifacius A, Tischer-Zimmermann S, Nay S, Jendretzky KF, et al. Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy. JAMA Neurol. 2026. https:\/\/doi.org\/10.1001\/jamaneurol.2025.5318.","journal-title":"JAMA Neurol"},{"key":"9824_CR103","doi-asserted-by":"publisher","unstructured":"Del Bello A, Treiner E. Immune Checkpoints in Solid Organ Transplantation. Biology (Basel). 2023;12(10). https:\/\/doi.org\/10.3390\/biology12101358.","DOI":"10.3390\/biology12101358"},{"issue":"12","key":"9824_CR104","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.ekir.2023.08.037","volume":"8","author":"WH Kitchens","year":"2023","unstructured":"Kitchens WH, Larsen CP, Badell IR. Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future. Kidney Int Rep. 2023;8(12):2529\u201345. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.037.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"9824_CR105","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1097\/tp.0000000000004459","volume":"107","author":"C Ferr\u00e1ndiz-Pulido","year":"2023","unstructured":"Ferr\u00e1ndiz-Pulido C, Leiter U, Harwood C, Proby CM, Guthoff M, Scheel CH, et al. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management. Transplantation. 2023;107(7):1452\u201362. https:\/\/doi.org\/10.1097\/tp.0000000000004459.","journal-title":"Transplantation"},{"key":"9824_CR106","doi-asserted-by":"publisher","unstructured":"Khan MA, Mehmood M, El Azzazi H, Shaikh S, Bhasin-Chhabra B, Gudsoorkar P, et al. Immune Checkpoint Inhibitors and Allograft Rejection Risk: Emerging Evidence Regarding Their Use in Kidney Transplant Recipients. J Clin Med. 2025;14(14). https:\/\/doi.org\/10.3390\/jcm14145152.","DOI":"10.3390\/jcm14145152"},{"issue":"5","key":"9824_CR107","doi-asserted-by":"publisher","first-page":"103004","DOI":"10.1016\/j.esmoop.2024.103004","volume":"9","author":"J Remon","year":"2024","unstructured":"Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, et al. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort. ESMO Open. 2024;9(5):103004. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103004.","journal-title":"ESMO Open"},{"issue":"4","key":"9824_CR108","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12539-021-00437-4","volume":"13","author":"K Miao","year":"2021","unstructured":"Miao K, Zhang L. Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review. Interdiscip Sci. 2021;13(4):801\u201314. https:\/\/doi.org\/10.1007\/s12539-021-00437-4.","journal-title":"Interdiscip Sci"},{"key":"9824_CR109","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.3389\/ti.2024.13322","volume":"37","author":"EB Barbir","year":"2024","unstructured":"Barbir EB, Abdulmoneim S, Dudek AZ, Kukla A. Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies. Transpl Int. 2024;37:13322. https:\/\/doi.org\/10.3389\/ti.2024.13322.","journal-title":"Transpl Int"},{"issue":"4","key":"9824_CR110","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","volume":"20","author":"AJ Portuguese","year":"2022","unstructured":"Portuguese AJ, Tykodi SS, Blosser CD, Gooley TA, Thompson JA, Hall ET. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. J Natl Compr Canc Netw. 2022;20(4):406\u2013e1611. https:\/\/doi.org\/10.6004\/jnccn.2022.7009.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"9824_CR111","doi-asserted-by":"publisher","first-page":"e1851","DOI":"10.1097\/txd.0000000000001851","volume":"11","author":"T Legris","year":"2025","unstructured":"Legris T, Sall\u00e9e M, Charmetant X, Thaunat O, Matignon M, Joher N, et al. Immune Checkpoint Inhibitors in Kidney Transplant Recipients: A French Multicenter Retrospective Cohort Study. Transpl Direct. 2025;11(9):e1851. https:\/\/doi.org\/10.1097\/txd.0000000000001851.","journal-title":"Transpl Direct"},{"issue":"6","key":"9824_CR112","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1172\/jci78088","volume":"125","author":"MD Rosenblum","year":"2015","unstructured":"Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228\u201333. https:\/\/doi.org\/10.1172\/jci78088.","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"9824_CR113","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/bf02786429","volume":"17","author":"R Eisenberg","year":"1998","unstructured":"Eisenberg R. Mechanisms of systemic autoimmunity in murine models of SLE. Immunol Res. 1998;17(1\u20132):41\u20137. https:\/\/doi.org\/10.1007\/bf02786429.","journal-title":"Immunol Res"},{"key":"9824_CR114","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","volume":"14","author":"MM Hossen","year":"2023","unstructured":"Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 2023;14:1198365. https:\/\/doi.org\/10.3389\/fimmu.2023.1198365.","journal-title":"Front Immunol"},{"key":"9824_CR115","doi-asserted-by":"publisher","first-page":"1197364","DOI":"10.3389\/fimmu.2023.1197364","volume":"14","author":"B Ibis","year":"2023","unstructured":"Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol. 2023;14:1197364. https:\/\/doi.org\/10.3389\/fimmu.2023.1197364.","journal-title":"Front Immunol"},{"issue":"11","key":"9824_CR116","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","volume":"18","author":"A Tison","year":"2022","unstructured":"Tison A, Garaud S, Chiche L, Cornec D, Kostine M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol. 2022;18(11):641\u201356. https:\/\/doi.org\/10.1038\/s41584-022-00841-0.","journal-title":"Nat Rev Rheumatol"},{"key":"9824_CR117","doi-asserted-by":"publisher","unstructured":"Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11). https:\/\/doi.org\/10.3390\/cells10112857.","DOI":"10.3390\/cells10112857"},{"issue":"9","key":"9824_CR118","doi-asserted-by":"publisher","first-page":"Itc65","DOI":"10.7326\/aitc201705020","volume":"166","author":"EL Matteson","year":"2017","unstructured":"Matteson EL, Dejaco C. Polymyalgia Rheumatica. Ann Intern Med. 2017;166(9):Itc65\u201380. https:\/\/doi.org\/10.7326\/aitc201705020.","journal-title":"Ann Intern Med"},{"key":"9824_CR119","doi-asserted-by":"publisher","unstructured":"Vergara-Dangond C, Cobo-Ib\u00e1\u00f1ez T, Cueva-N\u00e1jera G, Valverde-Garrido R, Garc\u00eda-Yubero C, Trives-Folguera L, et al. Prevalence of Psoriatic Arthritis in Patients with Moderate-to-Severe Psoriasis in the Era of Biologics and Small Molecule Therapies. J Clin Med. 2025;14(23). https:\/\/doi.org\/10.3390\/jcm14238359.","DOI":"10.3390\/jcm14238359"},{"key":"9824_CR120","doi-asserted-by":"publisher","first-page":"114148","DOI":"10.1016\/j.ejca.2024.114148","volume":"207","author":"MA Lopez-Olivo","year":"2024","unstructured":"Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, et al. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease. Eur J Cancer. 2024;207:114148. https:\/\/doi.org\/10.1016\/j.ejca.2024.114148.","journal-title":"Eur J Cancer"},{"issue":"12","key":"9824_CR121","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.21037\/atm-20-8124","volume":"9","author":"S Alexander","year":"2021","unstructured":"Alexander S, Swami U, Kaur A, Gao Y, Fatima M, Ginn MM, et al. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med. 2021;9(12):1033. https:\/\/doi.org\/10.21037\/atm-20-8124.","journal-title":"Ann Transl Med"},{"issue":"2","key":"9824_CR122","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/m17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. Ann Intern Med. 2018;168(2):121\u201330. https:\/\/doi.org\/10.7326\/m17-2073.","journal-title":"Ann Intern Med"},{"issue":"1","key":"9824_CR123","doi-asserted-by":"publisher","first-page":"2458948","DOI":"10.1080\/21645515.2025.2458948","volume":"21","author":"J Le","year":"2025","unstructured":"Le J, Sun Y, Deng G, Dian Y, Xie Y, Zeng F. Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy. Hum Vaccin Immunother. 2025;21(1):2458948. https:\/\/doi.org\/10.1080\/21645515.2025.2458948.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"9824_CR124","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12885-024-12256-z","volume":"24","author":"X Liu","year":"2024","unstructured":"Liu X, Li S, Ke L, Cui H. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):490. https:\/\/doi.org\/10.1186\/s12885-024-12256-z.","journal-title":"BMC Cancer"},{"issue":"17","key":"9824_CR125","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/jco.2017.77.6385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9824_CR126","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.jbspin.2025.105938","volume":"93","author":"A Tison","year":"2026","unstructured":"Tison A, Escoda T, Kostine M, Cornec D, Chiche L. Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review. Joint Bone Spine. 2026;93(1):105938. https:\/\/doi.org\/10.1016\/j.jbspin.2025.105938.","journal-title":"Joint Bone Spine"},{"key":"9824_CR127","doi-asserted-by":"publisher","first-page":"1712632","DOI":"10.3389\/fimmu.2025.1712632","volume":"16","author":"Y Dias","year":"2025","unstructured":"Dias Y, Silva V, de Carvalho MF, Herchenhorn R, Herchenhorn D. Safety and effectiveness of immune checkpoint inhibitors in patients with preexisting autoimmune diseases: a systematic review. Front Immunol. 2025;16:1712632. https:\/\/doi.org\/10.3389\/fimmu.2025.1712632.","journal-title":"Front Immunol"},{"issue":"10284","key":"9824_CR128","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4.","journal-title":"Lancet"},{"issue":"1","key":"9824_CR129","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27\u201342. https:\/\/doi.org\/10.1111\/ene.14108.","journal-title":"Eur J Neurol"},{"issue":"3","key":"9824_CR130","first-page":"175","volume":"37","author":"MM Goldenberg","year":"2012","unstructured":"Goldenberg MM. Multiple sclerosis review. P t. 2012;37(3):175\u201384.","journal-title":"P t"},{"issue":"10360","key":"9824_CR131","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(22)01272-7.","journal-title":"Lancet"},{"issue":"1","key":"9824_CR132","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R, et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024;23(1):81\u201394. https:\/\/doi.org\/10.1016\/s1474-4422(23)00369-1.","journal-title":"Lancet Neurol"},{"key":"9824_CR133","doi-asserted-by":"publisher","first-page":"877936","DOI":"10.3389\/fneur.2022.877936","volume":"13","author":"S Manenti","year":"2022","unstructured":"Manenti S, Orrico M, Masciocchi S, Mandelli A, Finardi A, Furlan R. PD-1\/PD-L Axis in Neuroinflammation: New Insights. Front Neurol. 2022;13:877936. https:\/\/doi.org\/10.3389\/fneur.2022.877936.","journal-title":"Front Neurol"},{"issue":"1","key":"9824_CR134","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.201847868","volume":"49","author":"I Mair","year":"2019","unstructured":"Mair I, Besusso D, Saul L, Patel SD, Ravindran R, McPherson RC, et al. PD-1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state. Eur J Immunol. 2019;49(1):112\u201320. https:\/\/doi.org\/10.1002\/eji.201847868.","journal-title":"Eur J Immunol"},{"issue":"1","key":"9824_CR135","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12974-018-1191-8","volume":"15","author":"DM Norden","year":"2018","unstructured":"Norden DM, Bethea JR, Jiang J. Impaired CD8 T cell antiviral immunity following acute spinal cord injury. J Neuroinflammation. 2018;15(1):149. https:\/\/doi.org\/10.1186\/s12974-018-1191-8.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"9824_CR136","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12576-024-00933-4","volume":"74","author":"NN Lasheen","year":"2024","unstructured":"Lasheen NN, Allam S, Elgarawany A, Aswa DW, Mansour R, Farouk Z. Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders. J Physiol Sci. 2024;74(1):46. https:\/\/doi.org\/10.1186\/s12576-024-00933-4.","journal-title":"J Physiol Sci"},{"issue":"1","key":"9824_CR137","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13578-022-00897-1","volume":"12","author":"CT Wu","year":"2022","unstructured":"Wu CT, Chu CI, Wang FY, Yang HY, Tseng WS, Chang CR, et al. A change of PD-1\/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer\u2019s Disease. Cell Biosci. 2022;12(1):162. https:\/\/doi.org\/10.1186\/s13578-022-00897-1.","journal-title":"Cell Biosci"},{"issue":"2","key":"9824_CR138","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nm.4022","volume":"22","author":"K Baruch","year":"2016","unstructured":"Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease. Nat Med. 2016;22(2):135\u20137. https:\/\/doi.org\/10.1038\/nm.4022.","journal-title":"Nat Med"},{"key":"9824_CR139","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fnagi.2019.00377","volume":"11","author":"Y Lin","year":"2019","unstructured":"Lin Y, Rajamohamedsait HB, Sandusky-Beltran LA, Gamallo-Lana B, Mar A, Sigurdsson EM. Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model. Front Aging Neurosci. 2019;11:377. https:\/\/doi.org\/10.3389\/fnagi.2019.00377.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"9824_CR140","doi-asserted-by":"publisher","first-page":"e16547","DOI":"10.1111\/ene.16547","volume":"32","author":"S Gelibter","year":"2025","unstructured":"Gelibter S, Saraceno L, Susani E, Pirro F, Sessa M, Protti A. Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis. Eur J Neurol. 2025;32(1):e16547. https:\/\/doi.org\/10.1111\/ene.16547.","journal-title":"Eur J Neurol"},{"issue":"36","key":"9824_CR141","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"issue":"12","key":"9824_CR142","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"issue":"3","key":"9824_CR143","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"Y Li","year":"2025","unstructured":"Li Y, Zheng Y, Huang J, Nie RC, Wu QN, Zuo Z, et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut. 2025;74(3):350\u201363. https:\/\/doi.org\/10.1136\/gutjnl-2024-333617.","journal-title":"Gut"},{"issue":"6","key":"9824_CR144","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1159\/000518104","volume":"10","author":"M Guti\u00e9rrez-Larra\u00f1aga","year":"2021","unstructured":"Guti\u00e9rrez-Larra\u00f1aga M, Gonz\u00e1lez-L\u00f3pez E, Roa-Bautista A, Rodrigues PM, D\u00edaz-Gonz\u00e1lez \u00c1, Banales JM, et al. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? Liver Cancer. 2021;10(6):545\u201360. https:\/\/doi.org\/10.1159\/000518104.","journal-title":"Liver Cancer"},{"issue":"5","key":"9824_CR145","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"key":"9824_CR146","doi-asserted-by":"publisher","unstructured":"Goff PH, Bhakuni R, Pulliam T, Lee JH, Hall ET, Nghiem P. Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer? Cancers (Basel). 2021;13(14). https:\/\/doi.org\/10.3390\/cancers13143415","DOI":"10.3390\/cancers13143415"},{"issue":"23","key":"9824_CR147","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.3390\/ijms262311271","volume":"26","author":"L Marcut","year":"2025","unstructured":"Marcut L, Brata RD, Barb AC, Manole A, Stef DG, Dumitru CS, et al. Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities. Int J Mol Sci. 2025;26(23):11271.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9824_CR148","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17(1):54. https:\/\/doi.org\/10.1186\/s13045-024-01581-2.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"9824_CR149","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044\u201360. https:\/\/doi.org\/10.3390\/curroncol29050247.","journal-title":"Curr Oncol"},{"issue":"8","key":"9824_CR150","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652\u201369. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006.","journal-title":"Cell"},{"issue":"4","key":"9824_CR151","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A, Primary. Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"1","key":"9824_CR152","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"1","key":"9824_CR153","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"5","key":"9824_CR154","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41(5):843\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019.","journal-title":"Immunity"},{"key":"9824_CR155","doi-asserted-by":"publisher","unstructured":"Storozynsky Q, Hitt MM. The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer. Int J Mol Sci. 2020;21(22). https:\/\/doi.org\/10.3390\/ijms21228877.","DOI":"10.3390\/ijms21228877"},{"issue":"2","key":"9824_CR156","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00281-022-00965-1","volume":"45","author":"F De Sanctis","year":"2023","unstructured":"De Sanctis F, Adamo A, Can\u00e8 S, Ugel S. Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. Semin Immunopathol. 2023;45(2):163\u201386. https:\/\/doi.org\/10.1007\/s00281-022-00965-1.","journal-title":"Semin Immunopathol"},{"issue":"3","key":"9824_CR157","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6.","journal-title":"Nat Immunol"},{"issue":"1","key":"9824_CR158","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 2019;50(1):195\u2013e21110. https:\/\/doi.org\/10.1016\/j.immuni.2018.12.021.","journal-title":"Immunity"},{"issue":"7637","key":"9824_CR159","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"1","key":"9824_CR160","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011.","journal-title":"Immunity"},{"issue":"4","key":"9824_CR161","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443\u201355. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017.","journal-title":"Cancer Cell"},{"key":"9824_CR162","doi-asserted-by":"publisher","unstructured":"Sindhu KK, Nehlsen AD, Lehrer EJ, Rowley JP, Stock RG, Galsky MD, et al. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy. Biomedicines. 2022;10(10). https:\/\/doi.org\/10.3390\/biomedicines10102481.","DOI":"10.3390\/biomedicines10102481"},{"issue":"7","key":"9824_CR163","doi-asserted-by":"publisher","first-page":"101621","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024;5(7):101621. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621.","journal-title":"Cell Rep Med"},{"key":"9824_CR164","doi-asserted-by":"publisher","unstructured":"Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW, et al. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(2). https:\/\/doi.org\/10.1136\/jitc-2022-005854.","DOI":"10.1136\/jitc-2022-005854"},{"key":"9824_CR165","doi-asserted-by":"publisher","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411). https:\/\/doi.org\/10.1126\/science.aar3593.","DOI":"10.1126\/science.aar3593"},{"issue":"8","key":"9824_CR166","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340. https:\/\/doi.org\/10.1172\/jci91190.","journal-title":"J Clin Invest"},{"key":"9824_CR167","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1200\/po.21.00182","volume":"5","author":"S Weber","year":"2021","unstructured":"Weber S, van der Leest P, Donker HC, Schlange T, Timens W, Tamminga M, et al. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. JCO Precis Oncol. 2021;5:1540\u201353. https:\/\/doi.org\/10.1200\/po.21.00182.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"9824_CR168","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","volume":"4","author":"JH Lee","year":"2018","unstructured":"Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol. 2018;4(5):717\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5332.","journal-title":"JAMA Oncol"},{"issue":"3","key":"9824_CR169","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.Cd-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2017;7(3):264\u201376. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0828.","journal-title":"Cancer Discov"},{"issue":"1","key":"9824_CR170","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13046-024-03074-z","volume":"43","author":"SC Pitts","year":"2024","unstructured":"Pitts SC, Schlom J, Donahue RN. Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. J Exp Clin Cancer Res. 2024;43(1):155. https:\/\/doi.org\/10.1186\/s13046-024-03074-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"9824_CR171","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.ekir.2024.02.1396","volume":"9","author":"IH Hanif","year":"2024","unstructured":"Hanif IH, Abdelrahim S, Al Shaarani M, Lu H, Ahmad R, Goswami S, et al. Immune Checkpoint Therapy-Induced Lupus Nephritis. Kidney Int Rep. 2024;9(5):1534\u20137. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1396.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"9824_CR172","doi-asserted-by":"publisher","first-page":"106391","DOI":"10.1016\/j.jinf.2024.106391","volume":"90","author":"NL Henriksen","year":"2025","unstructured":"Henriksen NL, Jensen P, Jensen LK. Immune checkpoint blockade in experimental bacterial infections. J Infect. 2025;90(2):106391. https:\/\/doi.org\/10.1016\/j.jinf.2024.106391.","journal-title":"J Infect"},{"key":"9824_CR173","doi-asserted-by":"publisher","first-page":"996469","DOI":"10.3389\/fimmu.2022.996469","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Du S, Zhao L, Jain S, Sahay K, Rizvanov A, et al. Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front Immunol. 2022;13:996469. https:\/\/doi.org\/10.3389\/fimmu.2022.996469.","journal-title":"Front Immunol"},{"key":"9824_CR174","doi-asserted-by":"publisher","unstructured":"Ghareghani M, Rivest S. The Synergistic Potential of Combining PD-1\/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer\u2019s Disease Treatment. Int J Mol Sci. 2023;24(13). https:\/\/doi.org\/10.3390\/ijms241310905.","DOI":"10.3390\/ijms241310905"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09824-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:03:48Z","timestamp":1787328228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":174,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9824"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09824-9","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No animal or human studies were performed for this review article.","order":1,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, ChatGPT tools were used to improve readability. The authors reviewed and edited the content as needed and took full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}